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Abstract
Background: Physical performance such as muscle strength or walking speed of patients with coronary artery
disease (CAD) is lower than that of people who do not have CAD and is related to mortality and re-admission rates.
Recent studies have shown that skeletal muscle strength, such as grip strength, was closely associated with cardiac
events. Physical performance testing is quick, safe, and inexpensive and provides a reliable assessment tool for
routine clinical practice. The aim of this meta-analysis is to clarify the association between physical performance
testing and the risk of cardiovascular events and mortality.
Methods/design: This meta-analysis will include male and female participants of any age in community settings
who have a history of the following conditions or procedures: myocardial infarction, or coronary revascularization
(coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, or coronary artery stent), angina
pectoris, heart failure, heart transplant, or coronary artery disease defined by angiography. We will search EMBASE
and MEDLINE, PubMed, and the Cochrane Library with no limitations on date, language, document type, or publication
status. Identified studies will be prospective and retrospective cohort studies. Physical performance will be defined as
upper extremity strength, lower extremity strength, walking speed, or other performance scale. Six review authors will
independently extract study characteristics from included studies. Participants will be divided into subgroups according
to age (middle-aged <65 years and elderly ≥65 years), diagnosis (coronary artery disease and heart failure) and follow-
up time (up to 12 months and over 12 months). We will pool hazard ratios of Cox proportional hazard models after
logarithmic transformation and perform the meta-analysis by using inverse-variance method.
Discussion: To our knowledge, this meta-analysis will be the first report to assess the association between physical
performance and cardiovascular events in CAD patients. We hope that these findings may help to estimate the
prognosis for CAD patients in clinical practice.
Systematic review registration: PROSPERO CRD42015020886.
Keywords: Coronary artery disease, Physical performance, Physical functions, Meta-analysis, Protocol, Secondary
prevention
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Background
As the life expectancy of patients with heart disease has
improved in recent years [1], secondary prevention of
re-admission and mortality of these patients is becoming
an important issue. Previous studies have shown that cir-
culating biomarkers (e.g., brain natriuretic peptide) [2]
and cardiac functions obtained by echocardiography
testing (e.g., left ventricular ejection fraction) [3, 4] affect
the mortality of these patients. Additionally, recent stud-
ies have shown that decreased physical performance
such as muscle strength or walking speed was closely re-
lated to mortality and cardiovascular events [5, 6]. That
physical performance of patients with coronary artery
disease (CAD) decreases to approximately 70 % relative
to that of people who do not have CAD [7] and is re-
lated to mortality and re-admission rates [8–10]. Our
previous study showed that a decrease in the walking
speed of CAD patients was a strong prognostic indicator
of cardiovascular events [5]. Furthermore, deterioration
in skeletal muscle strength such as grip strength [11] or
leg strength [6, 12] was closely associated with cardiac
events in CAD patients. Physical performance testing of-
fers a fast, safe, affordable, and reliable tool for clinical
practice. Therefore, further development of physical per-
formance testing is needed. However, the relationship
between physical performance testing and cardiovascular
events differs by diagnosis and age. For this reason, it is
necessary to divide patients into age groups (middle-
aged and elderly) or diagnosis groups (CAD and heart
failure) in order to verify the association between phys-
ical performance and cardiovascular events.
The aim of this meta-analysis is to clarify the associ-
ation between physical performance testing and risk of
cardiovascular events and mortality.
Methods/design
This meta-analysis was registered with PROSPERO (our
registration number: CRD42015020886). We based the
review methods on the guidelines of Meta-analysis of
Observational Studies in Epidemiology (MOOSE) [13],
Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) [14], and Preferred Reporting
Items for Systematic Reviews and Meta-Analyses Proto-
col (PRISMA-P) statement [15].
Search methods for identification of studies
We will search EMBASE and MEDLINE via Ovid SP,
PubMed, and the Cochrane Library via Wiley Online
Library with no restrictions on date/time, language,
document type, and publication status. Keywords will be
collected through experts’ opinion, literature review,
controlled vocabulary (Medical Subject Headings =
MeSH and Excerpta Medica Tree = EMTREE) and by
reviewing the primary search results. Also, to retrieve
cohort studies, we will use the search filter developed
by the BMJ Evidence Centre. Search strategies devel-
oped with the assistance of a medical information
specialist were reported in the Appendix. The process
of study selection is shown in a PRISMA flow dia-
gram (Fig. 1).
Inclusion and exclusion criteria
We will identify prospective and retrospective cohort
studies. Physical performance will be defined as upper
extremity strength (e.g., grip strength), lower extremity
strength (e.g., isometric or isotonic knee extension),
walking speed, or other performance scale (e.g., short
physical performance battery). We will include male and
female participants of any age in community settings
who have a history of the following: myocardial infarc-
tion, or coronary revascularization (coronary artery by-
pass grafting, percutaneous transluminal coronary
angioplasty, or coronary artery stent), angina pectoris,
heart failure, heart transplant, or coronary artery disease
defined by angiography. We will include studies that en-
rolled participants with these histories confirmed by the
medical record or administrative data.
We will exclude from the analysis those participants
who have dementia, low vision or blindness, orthopedic
surgery (e.g., hip or knee replacement and spinal sur-
gery), and paralysis due to stroke. If such histories are
not available in the paper, we will contact the authors of
the study to obtain the missing information.
Type of main outcomes
1. Mortality due to all cause
2. Mortality due to cardiovascular event
3. Re-hospitalization due to cardiovascular event
Data extraction and management
We will use a data extraction form for the study infor-
mation and outcome data. Six review authors (SY, TY,
SN, TI, YS, and MO) will be divided into three teams
(SY and TY, SN and TI, and YS and MO). They will in-
dependently extract study information from the included
studies, as follows:
1. Methods: study design, study setting, duration of
follow-up, and statistical analysis
2. Subjects: sample size, mean age, sex, history of
stroke, history of orthopedics, and history of cancer
3. Outcome measures: physical performance test,
concomitant medications, and excluded medications
4. Outcomes: main outcomes specified and collected
and time points reported
5. Notes: funding for trial and notable conflicts of
interest of trial authors
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If the authors disagree with each other in the teams,
we will resolve disagreements by discussion or by involv-
ing a third person (EO). One review author (SY) will
transfer data from a data extraction form to the Review
Manager file. We will double-check whether the data is
entered correctly by comparing the presented data in the
systematic review and research reports data. A second
review author (RM) will randomly check the extracted
data and characteristics against the source in order to
ensure accuracy.
Assessment of risk of bias
Two review authors (SY and TY) will independently
evaluate the risk of bias for each study according to the
Risk of Bias Assessment Tool: for Non-Randomized
Studies (RoBANS) [16]. We will resolve any disagree-
ments by discussion or by involving other authors (EO
and RM). We will evaluate the risk of bias assessment
tool, as follows:
1. Selection of participants
2. Confounding variables
3. Measurement of exposure
4. Blinding of outcome assessments
5. Incomplete outcome data
6. Selective outcome reporting
We will assess each domain as high, low, or unclear
risk of bias and determine our judgements using criteria
from the Cochrane Handbook [17].
Data synthesis and analysis
We will perform the meta-analysis independently by
each physical performance scale (e.g., upper extremity
strength or lower extremity strength). Participants will
be divided into subgroups according to age (middle-aged
< 65 years and elderly ≥ 65 years), diagnosis (CAD and
heart failure), and follow-up time (up to 12 months and
over 12 months). Data synthesis and analyses will be
performed using Review Manager version 5.3. We will
perform a meta-analysis using the hazard ratios after
logarithmic transformation by using inverse-variance
method. Furthermore, we will synthesize the hazard ra-
tios adjusted by variables of age and sex at least because
the physical performance scales are closely affected by
that factors. If we are able to pool more than 10 trials,
Fig. 1 PRISMA flow diagram
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we will create and examine funnel plot asymmetry visu-
ally in order to explore publication bias. If there is a sus-
picion of publication bias, we will carry out a simulation
to investigate the possible small-study effect. Heterogen-
eity will be assessed among included studies in each ana-
lysis using the chi-square test of heterogeneity and I2
statistic. Data from each study will be pooled using ran-
dom effects modeling where appropriate. To examine
the robustness of results, we will perform meta-analyses
using fixed-effect models after attributing less weight to
small trials. We will use these meta-analyses only if their
results differ from those of random effects models.
When an I2 score of >75 % is obtained, we will consider
heterogeneity to be substantial.
Discussion
To our knowledge, this will be the first meta-analysis to
assess the association between physical performance and
cardiovascular events in CAD patients. The main goals
for CAD patients are to prevent re-admission due to car-
diac events and improve mortality. Many cohort studies
have demonstrated that physical performance testing is
strongly associated with mortality and cardiac events for
CAD patients. Furthermore, physical performance test-
ing is a quick, safe, inexpensive, and reliable assessment
tool. We hope that our findings may help to estimate




1. Exp Heart Failure/OR Exp Ischemic Heart Disease/
OR Exp Cardiomegaly/OR Exp Cardiomyopathy/
OR Exp Coronary Artery Disease/OR Coronary
Artery Bypass Graft/OR Exp Coronary Blood
vessel/OR Exp Heart Surgery/OR Exp Percutaneous
Coronary Intervention/OR (Myocardial Ischemi$
OR Myocardial Infarct$ OR Cardiovascular Stroke
OR Ischemic Heart Disease? OR Angina? OR
((Heart OR Cardiac OR Myocardial) adj2 (Failure?
OR Surg$ OR Operat$ OR Resect$ OR Transplant$
OR Graft$ OR Massage?)) OR CHF OR CABG OR
Coronary OR Aortocoronary OR Sinus Node Arter$
OR Intracardiac Surg$ OR Cardiosurg$ OR Annu
loplast$ OR Valve Annul$ OR Cardiomyoplast$ OR
Cardioplegia? OR Heart Bypass$ OR Ventric$ Bypass$
OR Cavopulmonary Anastomos$ OR Cavopulmonary
Shunt? OR Heart Valv$ OR Cardiac Valv$ OR Aort$
Valv$ OR Mitral Valv$ OR Pulmonary Valv$ OR
Tricuspid Valv$ OR ((Heart OR Myocardial OR Trans
myocardial OR Trans Myocardial) adj2 Revasculari$)
OR Internal Mammary Artery Implant$ OR Perica
rdiostom$ OR Pericardiectom$ OR Pericardectom$
OR Pericardiotom$ OR Pericardotom$ OR Pericar
diocentes$ OR Pericardial Aspirat$ OR Pericardium
Puncture? OR Rotational Atherectom$ OR Epicardi$
Mapping OR Heart Aneurysmectom$ OR Valvu
loplast$ OR Valv$ Repair$ OR Valvotom$ OR Valvu
lotom$ OR ((Prosthe$ OR Artificial OR Mechanical)
adj2 Valve?) OR Heart Enlargement? OR Enlarged
Heart OR Cardiac Hypertroph$ OR Heart Hyper
troph$ OR Cardiomyopath$ OR Ventric$ Hyper
troph$ OR Atrial Dilatation OR Atrial Enlargement
OR Atrial Hypertroph$ OR Atriomegaly OR Atrium
Dilatation OR Atrium Enlargement OR Atrium
Hypertroph$ OR Cardiac Muscle Hypertroph$ OR
Heart Hyperplasia OR Heart Muscle Hypertroph$ OR
Myocardial Hypertroph$ OR Myocardium Hyper
troph$ OR Ventric$ Wall Thickness OR Myocardial
Disease? OR Myocardiopath$ OR Adhalinopath$ OR
Sarcoglycanopath$ OR Antopol Disease OR Ventric$
Dysplasia OR Trypanosomiasis OR Carditis OR
Endocardial Fibroelastos$ OR Endomyocardial Fibroe
lastosis OR Endomyocardial Fibros$ OR Myocardial
Ischemic Reperfusion Injur$ OR Myocarditi$ OR
Obstructive Asymmetric Septal Hypertroph$ OR
Heart Amyloidosis OR Heart Myopath$ OR Cardiac
Amyloidosis OR Oculocraniosomatic).ti,ab.
2. Exp Leg/OR Exp Arm/AND (Strength OR Force
OR Power).ti,ab.
3. Exp Walking/ OR Muscle Strength/OR (Postural
Balance OR Musculoskeletal Equilibrium OR
Postural Equilibrium OR Gait OR Gaits OR Stair?
Navigation? OR ((Hand OR Hands OR Pinch OR
Leg OR Legs OR Lower Extremit$ OR Lower
Limb? OR Membrum Inferius OR Upper Extremit$
OR Upper Limb? OR Membrum Superius OR
Muscle? OR Muscle? Dynamic OR Muscular OR
Muscular Dynamic OR Arm OR Arms) adj
(Strength OR Force OR Power)) OR Grip OR Grips
OR Grasp? OR Walk$ OR Locomotion OR
Ambulation OR (Physical adj (Balance OR Function
OR Performance OR Strength OR Activit$))).ti,ab.
4. 2 OR 3
5. Exp cohort analysis/OR Exp longitudinal study/OR
Exp prospective study/OR Exp follow up/OR Co
hort$.tw.
6. 1 AND 4 AND 5
7. limit 6 to human
8. limit 7 to exclude medline journals
B. MEDLINE
1. Exp Heart Failure/OR Exp Myocardial Ischemia/OR
Exp Cardiomegaly/OR Exp Cardiomyopathies/OR
Exp Coronary Disease/OR Exp Coronary Artery
Bypass/OR Exp Coronary Vessels/OR Exp Cardiac
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Surgical Procedures/OR Exp Percutaneous Coronary
Intervention/OR (Myocardial Ischemi$ OR Myo
cardial Infarct$ OR Cardiovascular Stroke? OR
Ischemic Heart Disease? OR Angina? OR ((Heart OR
Cardiac OR Myocardial) adj2 (Failure? OR Surg$ OR
Operat$ OR Resect$ OR Transplant$ OR Graft$ OR
Massage?)) OR CHF OR CABG OR Coronary OR
Aortocoronary OR Sinus Node Arter$ OR Intra
cardiac Surg$ OR Cardiosurg$ OR Annuloplast$ OR
Valve Annul$ OR Cardiomyoplast$ OR Cardioplegia?
OR Heart Bypass$ OR Ventric$ Bypass$ OR Cav
opulmonary Anastomos$ OR Cavopulmonary Shunt?
OR Heart Valv$ OR Cardiac Valv$ OR Aort$ Valv$
OR Mitral Valv$ OR Pulmonary Valv$ OR Tricuspid
Valv$ OR ((Heart OR Myocardial OR Trans
myocardial OR Trans Myocardial) adj2 Revasculari$)
OR Internal Mammary Artery Implant$ OR Pericar
diostom$ OR Pericardiectom$ OR Pericardectom$
OR Pericardiotom$ OR Pericardotom$ OR Pericar
diocentes$ OR Pericardial Aspirat$ OR Pericardium
Puncture? OR Rotational Atherectom$ OR Epicardi$
Mapping OR Heart Aneurysmectom$ OR Valvu
loplast$ OR Valv$ Repair$ OR Valvotom$ OR
Valvulotom$ OR ((Prosthe$ OR Artificial OR Me
chanical) adj2 Valve?) OR Heart Enlargement? OR
Enlarged Heart OR Cardiac Hypertroph$ OR Heart
Hypertroph$ OR Cardiomyopath$ OR Ventric$
Hypertroph$ OR Atrial Dilatation OR Atrial Enlar
gement OR Atrial Hypertroph$ OR Atriomegaly OR
Atrium Dilatation OR Atrium Enlargement OR
Atrium Hypertroph$ OR Cardiac Muscle Hyper
troph$ OR Heart Hyperplasia OR Heart Muscle
Hypertroph$ OR Myocardial Hypertroph$ OR Myo
cardium Hypertroph$ OR Ventric$ Wall Thickness
OR Myocardial Disease? OR Myocardiopath$ OR
Adhalinopath$ OR Sarcoglycanopath$ OR Antopol
Disease OR Ventric$ Dysplasia OR Trypanosomiasis
OR Carditis OR Endocardial Fibroelastos$ OR
Endomyocardial Fibroelastosis OR Endomyocardial
Fibros$ OR Myocardial Ischemic Reperfusion Injur$
OR Myocarditi$ OR Obstructive Asymmetric Septal
Hypertroph$ OR Heart Amyloidosis OR Heart Myo
path$ OR Cardiac Amyloidosis OR Oculocrani
osomatic).ti,ab.
2. Exp Lower Extremity/OR Exp Upper Extremity/
AND (Strength OR Force OR Power).ti,ab.
3. Postural Balance/OR Gait/OR Exp Muscle
Strength/OR Muscle Strength Dynamometer/OR
Exp Walking/OR (Postural Balance OR Muscu
loskeletal Equilibrium OR Postural Equilibrium OR
Gait OR Gaits OR Stair? Navigation? OR ((Hand
OR Hands OR Pinch OR Leg OR Legs OR Lower
Extremit$ OR Lower Limb? OR Membrum Inferius
OR Upper Extremit$ OR Upper Limb? OR
Membrum Superius OR Muscle? OR Muscle?
Dynamic OR Muscular OR Muscular Dynamic OR
Arm OR Arms) adj (Strength OR Force OR Power))
OR Grip OR Grips OR Grasp? OR Walk$ OR
Locomotion OR Ambulation OR (Physical adj
(Balance OR Function OR Performance OR
Strength OR Activit$))).ti,ab.
4. 2 OR 3
5. Exp cohort studies/ or Cohort$.tw. or Controlled
clinical trial.pt.
6. Epidemiologic methods/
7. Limit 2 to yr = 1971-1988
8. 5 OR 7
9. 1 and 4 and 8
10. limit 9 to humans
C. PubMed
("Myocardial Ischemia"[tiab] OR "Myocardial Infarc-
tion"[tiab] OR "Cardiovascular Stroke"[tiab] OR "Cardio-
vascular Disease"[tiab] OR "Cardiovascular Events"[tiab]
OR "Ischemic Heart Disease"[tiab] OR Angina[tiab] OR
((Heart[tiab] OR Cardiac[tiab] OR Myocardial[tiab])
AND (Failure[tiab] OR Surgery[tiab] OR Operation[tiab]
OR Transplantation[tiab] OR Graft[tiab])) OR CHF[tiab]
OR CABG[tiab] OR Coronary[tiab] OR Aortocoronary[-
tiab] OR "Intracardiac Surgery"[tiab] OR Cardiosurgery[-
tiab] OR Annuloplasty[tiab] OR "Valve Annulo
plasty"[tiab] OR Cardiomyoplasty[tiab] OR Cardiople-
gia[tiab] OR "Heart Bypass"[tiab] OR "Ventricular Bypas-
s"[tiab] OR "Cavopulmonary Shunting"[tiab] OR Peri
cardiostomy[tiab] OR Pericardiectomy[tiab] OR Pericar-
dectomy[tiab] OR Pericardiotomy[tiab] OR Pericardoto-
my[tiab] OR "Pericardial Aspiration"[tiab] OR "Peri
cardium Puncture"[tiab] OR "Rotational Atherectomy"[-
tiab] OR Valvuloplasty[tiab] OR "Valve Repair"[tiab] OR
Valvotomy[tiab] OR Valvulotomy[tiab] OR "Prosthetic
Valve"[tiab] OR "Artificial Valve"[tiab] OR "Mechanical
Valve"[tiab] OR "Heart Enlargement"[tiab] OR "Enlarged
Heart"[tiab] OR "Cardiac Hypertrophy"[tiab] OR "Heart
Hypertrophy"[tiab] OR Cardiomyopathy[tiab] OR "Car-
diac Muscle Hypertrophy"[tiab] OR "Heart Muscle
Hypertrophy"[tiab] OR "Myocardial Hypertrophy"[tiab]
OR "Myocardium Hypertrophy"[tiab] OR "Ventricular
Wall Thickness"[tiab] OR "Myocardial Disease"[tiab] OR
Antopol Disease[tiab] OR Trypanosomiasis[tiab] OR
Carditis[tiab] OR "Endocardial Fibroelastosis"[tiab] OR
"Endomyocardial Fibroelastosis"[tiab] OR "Endomyocar-
dial Fibrosis"[tiab] OR "Myocardial Ischemic Reperfusion
Injury"[tiab] OR Myocarditis[tiab] OR "Heart Myo-
pathy"[tiab]) AND ("Postural Balance"[tiab] OR "Postural
Equilibrium"[tiab] OR Gait[tiab] OR Gaits[tiab] OR
"Stair Navigation"[tiab] OR ((Hand[tiab] OR Hands[tiab]
OR Pinch[tiab] OR Leg[tiab] OR Legs[tiab] OR
(Lower[tiab] AND Extremit*[tiab]) OR (Lower[tiab]
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AND Limb*[tiab]) OR (Upper[tiab] AND Extremit*[tiab])
OR (Upper[tiab] AND Limb*[tiab]) OR Muscle*[tiab] OR
(Muscle*[tiab] AND Dynamic[tiab]) OR Muscular[tiab]
OR Arm[tiab] OR Arms[tiab]) AND (Strength[tiab] OR
Force[tiab] OR Power[tiab])) OR Grip[tiab] OR Grips[tiab]
OR Grasp*[tiab] OR Walk*[tiab] OR Locomotion[tiab] OR
Ambulation[tiab] OR (Physical[tiab] AND (Balance[tiab]
OR Function[tiab] OR Performance[tiab] OR Strength[tiab]
OR Activit*[tiab]))) AND ("Cohort Studies"[MeSH] OR
Cohort*[All Fields] OR "Controlled Clinical Trial"[pt] OR
Prospective[tiab] OR Follow-Up[tiab] OR "Follow Up"[tiab]
OR Followup[tiab]) NOT MEDLINE[sb]
D. Cochrane Library
#1 MeSH descriptor: [Heart Failure] explode all trees
#2 MeSH descriptor: [Myocardial Ischemia] explode
all trees
#3 MeSH descriptor: [Cardiomegaly] explode all trees
#4 MeSH descriptor: [Cardiomyopathies] explode all
trees
#5 MeSH descriptor: [Coronary Disease] explode all
trees
#6 MeSH descriptor: [Coronary Artery Bypass] explode
all trees
#7 MeSH descriptor: [Coronary Vessels] explode all
trees
#8 MeSH descriptor: [Cardiac Surgical Procedures]
explode all trees
#9 MeSH descriptor: [Percutaneous Coronary Inter-
vention] explode all trees
#10 (Myocardial Ischemi* or Myocardial Infarct* or
Cardiovascular Stroke* or Ischemic Heart Disease* or
Angina* or ((Heart or Cardiac or Myocardial) near/2
(Failure* or Surg* or Operat* or Resect* or Transplant*
or Graft* or Massage*)) or CHF or CABG or Coronary
or Aortocoronary or Sinus Node Arter* or Intracardiac
Surg* or Cardiosurg* or Annuloplast* or Valve Annul*
or Cardiomyoplast* or Cardioplegia* or Heart Bypass* or
Ventric* Bypass* or Cavopulmonary Anastomos* or
Cavopulmonary Shunt* or Heart Valv* or Cardiac Valv*
or Aort* Valv* or Mitral Valv* or Pulmonary Valv* or
Tricuspid Valv* or ((Heart or Myocardial or Transmyo-
cardial or Trans Myocardial) near/2 Revasculari*) or In-
ternal Mammary Artery Implant* or Pericardiostom* or
Pericardiectom* or Pericardectom* or Pericardiotom* or
Pericardotom* or Pericardiocentes* or Pericardial Aspirat*
or Pericardium Puncture* or Rotational Atherectom* or
Epicardi* Mapping or Heart Aneurysmectom* or Valvulo-
plast* or Valv* Repair* or Valvotom* or Valvulotom* or
((Prosthe* or Artificial or Mechanical) near/2 Valve*) or
Heart Enlargement* or Enlarged Heart or Cardiac Hyper-
troph* or Heart Hypertroph* or Cardiomyopath* or
Ventric* Hypertroph* or Atrial Dilatation or Atrial
Enlargement or Atrial Hypertroph* or Atriomegaly or
Atrium Dilatation or Atrium Enlargement or Atrium
Hypertroph* or Cardiac Muscle Hypertroph* or Heart
Hyperplasia or Heart Muscle Hypertroph* or Myocardial
Hypertroph* or Myocardium Hypertroph* or Ventric*
Wall Thickness or Myocardial Disease* or Myocardio-
path* or Adhalinopath* or Sarcoglycanopath* or Antopol
Disease or Ventric* Dysplasia or Trypanosomiasis or
Carditis or Endocardial Fibroelastos* or Endomyocardial
Fibroelastosis or Endomyocardial Fibros* or Myocardial
Ischemic Reperfusion Injur* or Myocarditi* or Obstructive
Asymmetric Septal Hypertroph* or Heart Amyloid-
osis or Heart Myopath* or Cardiac Amyloidosis or
Oculocraniosomatic):ti,ab
#11 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
or #10
#12 MeSH descriptor: [Lower Extremity] explode all
trees
#13 MeSH descriptor: [Upper Extremity] explode all
trees
#14 (Strength or Force or Power):ti,ab
#15 MeSH descriptor: [Postural Balance] explode all
trees
#16 MeSH descriptor: [Gait] explode all trees
#17 MeSH descriptor: [Muscle Strength] explode all
trees
#18 MeSH descriptor: [Muscle Strength Dynamometer]
explode all trees
#19 MeSH descriptor: [Walking] explode all trees
#20 (Postural Balance or Musculoskeletal Equilibrium
or Postural Equilibrium or Gait or Gaits or Stair* Naviga-
tion* or ((Hand or Hands or Pinch or Leg or Legs or
Lower Extremit* or Lower Limb* or Membrum Inferius
or Upper Extremit* or Upper Limb* or Membrum Superius
or Muscle* or Muscle* Dynamic or Muscular or Muscular
Dynamic or Arm or Arms) near/1 (Strength or Force
or Power)) or Grip or Grips or Grasp* or Walk* or
Locomotion or Ambulation or (Physical near/1 (Balance
or Function or Performance or Strength or Activit*))):ti,ab
#21 (#12 or #13) and #14
#22 #15 or #16 or #17 or #18 or #19 or #20 or #21
#23 #11 and #22
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